60 Degrees Pharmaceuticals (SXTP) CEO boosts holdings with stock buy
Rhea-AI Filing Summary
60 Degrees Pharmaceuticals reported that President and CEO Geoffrey Dow, who is also a director, bought 9,670 shares of its common stock on December 15, 2025 at $0.8024 per share. Following this purchase, he directly owns 59,618 common shares of the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 9,670 | $0.8024 | $8K |
FAQ
What insider transaction did 60 Degrees Pharmaceuticals (SXTP) disclose?
The company disclosed that President and CEO Geoffrey Dow purchased 9,670 shares of its common stock on December 15, 2025 at a price of $0.8024 per share.
Who is the reporting person in this SXTP insider transaction?
The reporting person is Geoffrey Dow, who serves as President, CEO, and Director of 60 Degrees Pharmaceuticals, Inc.
Was the SXTP insider position reported as direct or indirect ownership?
The filing shows the 59,618 shares as held with direct (D) ownership by Geoffrey Dow.
On what date did the SXTP insider stock purchase occur?
The purchase of 9,670 shares of 60 Degrees Pharmaceuticals common stock occurred on December 15, 2025.
What type of security did the 60 Degrees Pharmaceuticals CEO acquire?
Geoffrey Dow acquired shares of common stock of 60 Degrees Pharmaceuticals, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.